|
Working Groups
|
|
The work of the Organization is conducted through scientific meetings,
consultations and working groups with funds of the OECI. A limited number
of working groups and special activities are designed to sustain the main
objectives of the Organization, which are:
|
|
|
WGA&D;: Working Group Accreditation and Designation of cancer centers in Europe
|
|
|
Chairperson: Mahasti Saghatchian
Read more...
|
|
|
WGE&T;: Working Group Education & Training
|
|
|
Chairperson: Angelo Paradiso
|
|
|
The Education and Training Working Group: “E&T; WG” aims to stimulate the international
mobility for young scientists, to improve the capabilities of research and development
and to promote continuing education for experienced scientists and clinicians.
The main goal of the E&T; WG is to promote the establishment of a European Area for E&T;
in the cancer field, to stimulate better relationship among the members of the GEIE-OECI
(the Group) and defining in the meantime a better connection with external related bodies.
With the plan of activities of the E&T; WG the OECI hopes to contribute to give a practical
answer to the Lisbon goals, to tackle fragmentation of training and to share knowledge and
facilities among CCC, to facilitate the launch of new research initiatives, to reinforce
existing successful actions, to improve knowledge on new emerging fields, to exchange
personnel with industries and vice-versa.
Read more...
|
|
|
WGCB: Cancer Biobanks
|
|
|
Chairperson: Peter Riegman
|
|
|
The OECI Cancer Biobanks working group has the task to standardize and harmonize the collection
of biological samples in European Comprehensive Cancer centers for cancer applications.
Read more...
|
|
|
WGMP: Working Group Molecular Pathobiology |
|
|
Chairperson: Antonio Llombart-Bosch
|
|
|
(in progress)
|
|
|
START Project Activity
|
|
|
Chairperson: Lisa Licitra
|
|
|
START stands for “State-of-the-Art Oncology in Europe”. In fact, it is meant to be an online
data base on state-of-the-art knowledge about cancer diagnostics and treatment, with a European
perspective. This means that the statements on main clinical “options” are codified and accompanied
by a codified “levels of evidence” and “type of basis”, according to a classification originally
devised (Figure 1). The background has been detailed in the literature (Ann. Oncol. 1999; 10: 769-774).
START is an independent Program. It was established in 1995 within the ESO. As from September 2002,
it is one of the services also supported by Alleanza Contro il Cancro (“Alliance Against Cancer” - ACC),
the Italian cancer network, under the auspices of the Italian Health Ministry. Formally, START is a data base,
freely accessible on the Internet at www.startoncology.net.
It contains chapters on single human malignant neoplasms, as well as some chapters on cancer-related topics
(antiemetic therapy, pain therapy, and more). Original chapters are written in English, subsequently
translated into Italian and eventually adapted (only in Italian) for patients and non professionals in general
Read more...
|
|
|
WIN Project Activity
|
|
|
Chairperson: Thomas Tursz
|
|
|
Today there are more than 14,000,000 new cancers each year world wide, and less than 50% are cured. The main cause is
late detection and inappropriate treatment based on statistical population approaches. The shift from past to future
medicine based on prevention, early diagnosis and efficient individualized treatments could be dramatically accelerated
from 50 years to a 3-5 year timeline, through a coordinated efficient worldwide initiative bringing together the élite
of academic industry and a coordinated governmental strategy. To this aim, the WIN Consortium (worldwide innovative
networking in cancer personalized medicine) is a joint initiative of the Institut Gustave Roussy and the University
of Texas M. D. Anderson Cancer Center (MDACC), in association with 26 élite leading cancer care institutions in Europe,
United States of America, Canada, Middle East and Asia. All European institutes are OECI members. The major goal of the
WIN Consortium is to accelerate translation of ground-breaking discoveries made in personalized cancer medicine from
the bench to the bedside and to promote new types of interactions between academy and industry worldwide.
This is a worldwide initiative, across the continents, and the WIN Consortium aims to build new strategic alliances
in oncology, to improve early diagnosis of cancer, and to establish new treatment strategies based on rational
individualized selection of treatments.
The management of the WIN Consortium is assured by Dr. Vladimir Lazar from IGR (France), in his capacity of co-ordinator
of the WIN Consortium and Chairman of the Steering Committee, and by Pr. John Mendelsohn from MDACC (USA), in his capacity
of President of the WIN Consortium. The management proposes a strategic plan based on the most advanced scientific and
technologic achievements and brings together worldwide key opinion leaders in oncology.
The WIN Consortium is extremely focused on five objectives:
1. early diagnosis as the most efficient way to improve clinical outcome;
2. individualized treatment and therapeutic combinations based on innovative technologies available within the consortium;
3. strategic positioning with pharmaceutical companies with innovative drug associations and efficient clinical trials conducted simultaneously across the continents;
4. standardisation, harmonization and worldwide coordination of academics;
5. education and scientific dissemination through its annual WIN symposium
The WIN consortium is an operational organization that has decided to join forces and knowledge in order to considerably
improve health care in oncology and to lead to important societal benefits in terms of cost of cancer health care.
|
|
|
|